Michael Katz

Interests

No activities entered.

Courses

Scholarly Contributions

Books

• Matthias, K. R., & Katz, M. (2023). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. McGraw-Hill.
• Matthias, K. R., & Katz, M. (2020). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 5th ed. McGraw Hill.
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. (2017). Pharmacotherapy Principles and Practice Study Guide, 4th Edition. NY: McGraw-Hill.
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. A. (2016). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 4th ed. McGraw Hill.
• Chisholm-Burns, M. A., Matthias, K. R., & Katz, M. (2013). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 3rd ed. McGraw Hill.
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. A. (2013). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 3rd ed.
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. A. (2009). Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 1st ed. McGraw Hill.

Chapters

• Katz, M., & Matthias, K. R. (2023). Applying pharmacotherapy principles and practice: how to use this study guide. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. Access Pharmacy: McGraw Hill.
• Katz, M. (2022). Anxiety Disorders. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed.(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M. (2022). COPD. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed.(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M. (2022). Chronic Pain. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed.(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M. (2022). Hypothyroidism. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed.(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M. (2022). Iron Deficiency Anemia. In In: Matthias KRPharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M., & Ieng, P. (2022). Peptic Ulcer Disease. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed.(pp on-line). Access Pharmacy: McGraw-Hill.
• Katz, M., & Jacisin, T. (2022). Hematology: Red and white blood cell disorders. In Basic skills in interpreting laboratory data, 7th ed.(pp 355-76). ASHP.
• Katz, M. (2020). Peptic Ulcer Disease. In Pharmacotherapy Principles and Practice Study Guide, 5/e(pp online).
• Matthias, K. R., & Katz, M. (2020). Applying Pharmacotherapy Principles and Practice: How to Use This Study Guide. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 5th ed. McGraw Hill.
• Katz, M. (2020). Chronic pain management. In Pharmacotherapy Principles and Practice Study Guide, 5/e(pp online).
• Katz, M. (2020). Hypothyroidism. In Pharmacotherapy Principles and Practice Study Guide, 5/e(pp online).
• Katz, M. (2017). Hypothyroidism. In Pharmacotherapy Casebook.
• Katz, M. (2016). Thyroid Disorders. In Pharmacotherapy Principles and Practice.
• Katz, M. (2017). Peptic ulcer disease. In Pharmacotherapy Principles and Practice Study Guide, 4th edition.
• Katz, M., & Fallon, E. (2017). Chronic pain management. In Pharmacotherapy Principles and Practice Study Guide, 4th edition.
• Katz, M., & Nimworapan, M. (2017). Hypothyroidism. In Pharmacotherapy Principles and Practice Study Guide, 4th edition.
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. (2017). Applying pharmacotherapy principles and practice: How to use this study guide. In Pharmacotherapy Principles and Practice Study Guide, 4th edition(p. 19).
• Katz, M., Matthias, K. R., & Chisholm-Burns, M. A. (2016). Applying Pharmacotherapy Principles and Practice: How to Use This Study Guide. In Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 4th ed. McGraw Hill.
• Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., Katz, M., Vainrub, S., Hoyland, M. N., , Katz, M., et al. (2014). Chronic Kidney Disease: End Stage Renal Disease. In Pharmacotherapy Principles and Practice Study Guide, Third Edition(p. 4). McGraw Hill Education.

Journals/Publications

• Alshehri, S., Eljaaly, K., Alshibani, M., & Katz, M. (2020). Impact of single-dose systemic glucocorticoids on blood leukocytes in hospitalized adults. J Appl Hematol. doi:10.4103/joah.joah_24_20
• Badreldin, H., Thabit, A., Almangour, T., Alessa, M., Eljaaly, K., Fanikos, J., & Katz, M. (2020). Pursuing postgraduate pharmacy training in the United States for international pharmacy graduates: Approaches, current status challenges and future perspectives. J Am Coll Clin Pharm. doi:DOI: 10.1002/jac5.1339
• Nakanishi, M., Mizuno, T., Mizokami, F., Koseki, T., Takahashi, K., Tsuboi, N., Katz, M., Lee, J., & Yamada, S. (2020). Impact of pharmacist intervention for blood pressure control in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. J Clin Pharm Ther. doi:10.1111/jcpt.13262
• Nathisuwan, S., Pattharachayakul, S., Subonkot, S., Doungngern, T., Jones, S., Engle, J., Lau, A., Katz, M., Moreton, E., & Ryan, M. (2020). US-Thai Consortium for the development of pharmacy education in Thailand. J Am Coll Clin Pharm, 3, 935-46.
• Subongkot, S., Ryan, M., Pattharachayakul, S., Nathisuwan, S., Moreton, J. E., Lau, A., Katz, M. D., Jones, S. M., Engle, J. P., & Doungngern, T. (2020). U.S.‐Thai Consortium for the Development of Pharmacy Education in Thailand ‐ History, Progress, and Impact. JACCP. doi:10.1002/JAC5.1262
• Al-Dahir, S., Alsharif, N. Z., Gleason, S. E., Tofade, T., Flores, E. K., Katz, M., & Dornblaser, E. K. (2017). Current Practices in Hosting Non-US Pharmacy Students at US Pharmacy Schools in Experiential Clerkships. American journal of pharmaceutical education, 81(9), 6004.
  More info

  Objective: To provide specific considerations for hosting non-U.S. pharmacy students at U.S.-based colleges/schools of pharmacy (C/SOP) for experiential clerkships and training. Findings: A literature review (2000-2016) in PubMed, Google Scholar and IPA databases was conducted using specific keywords. Recommendations and future directions for development of experiential rotations for non-U.S. students in U.S. experiential rotations are presented for both the home and host country. Summary articles and best practices across the disciplines, as well as expert opinion, were found across U.S. models for hosting non-U.S. students in advanced practice rotations in the medical disciplines. Consistent themes regarding legal agreements, acculturation, standardized calendars and social and safety considerations were considered for inclusion in the final document. Conclusion: Development of a successful experiential rotation/training for non-U.S. students requires consideration for well-developed objectives, qualified preceptors, multitude of legal and cultural considerations and recommendations for longevity and sustainability.
• Bogari, H., Patanwala, A. E., Cosgrove, R., & Katz, M. D. (2014). Risk-assessment and pharmacologic prophylaxis of venus thromboembolism in hospitalized patients with chronic liver disease. Thrombosis Research, epub(epub), epub.
• Johnson-Clague, M., DiLeo, J., Katz, M. D., & Patanwala, A. E. (2014). Effect of ful correction versus partial correction of elevated blood glucose in the emergency department on hospital length of stay. Am J Ther, epub(epub), epub.
• Douglas, R. M., Parker, L. N., Katz, M., Cosgrove, R. A., & Katz, M. D. (2012). Evaluation of Post-Operative Venous Thromboembolism Prophylaxis in Lung Transplant Patients. J Hematol.
• Akaho, E., Nakagawa, S., & Katz, M. (2010). Promotion and enhancement of communication and discussion skills through clinical pharmacy courses taught in English at a Japanese School of Pharmacy. Pharmacy Education, 10(2), 149-156.
  More info

  Abstract: In 2006, the Japanese pharmacy education system shifted from a 4-year to a 6-year curriculum One of the major emphases of the new 6-year pharmacy curriculum is patient-centered clinical pharmacy, and it is expected that the students will leave the program with good communication skills not only with other health professionals but also with patients. Teaching pharmacy students to become excellent communicators is no easy task, and in the previous 4-year Japanese pharmacy curriculum, pharmacy practice and communication skills were de-emphasized in favor of basic science, laboratory practice and research skills. One strategy to enhance students' communication and critical thinking skills is the use of small group discussions and case-based learning. We evaluated the impact of a small group case-based discussion in a group of pharmacy students in Japan. Students' motivation to learn clinical pharmacy and their perceptions of the importance of learning communication skills were evaluated. After the session, most students felt that they should receive more training in clinical pharmacy and communication. © 2010 FIP.
• Ishikawa, K., Katz, M., & Hill-Besinque, K. (2010). Graduate programs in advanced pharmacy practice in oncology in Japan. American Journal of Pharmaceutical Education, 74(6), 1-8.
• Ishikawa, K., Katz, M., & Hill-Besinque, K. (2010). Graduate programs in advanced pharmacy practice in oncology in Japan.. American journal of pharmaceutical education, 74(6), 111-.
  More info

  PMID: 21045953;PMCID: PMC2933020;
• Katz, M., Scherger, J., Conard, S., Montejano, L., & Chang, S. (2010). Healthcare costs associated with switching from brand to generic levothyroxine. American Health and Drug Benefits, 3(2), 127-134.
  More info

  Abstract: Background: Controversy exists over the true therapeutic equivalence of branded and generic levothyroxine-the drug of choice for treating hypothyroidism-so professional societies recommend against switching between different formulations of the drug and suggest that patients who do switch be monitored. Payers typically encourage switching to generic drugs because of lower drug acquisition costs. Objective: To evaluate the impact of switching levothyroxine formulations on actual healthcare costs. Methods: Patients with hypothyroidism and at least 6 months of branded levothyroxine therapy were identified from a large healthcare claims database. Patients who subsequently switched to another levothyroxine formulation and could be followed for 6 months postswitch were matched to demographically similar patients who were continuous users of branded levothyroxine. Pre- and postswitch healthcare costs for each group were compared. Results: The savings in prescription drug costs after switching from branded to generic levothyroxine are offset by increases in costs for other healthcare services, such that switching is actually associated with an increase, not a decrease, in total healthcare costs. Conclusion: In the absence of cost-savings, there is no clear rationale for switching patients from brand to generic levothyroxine.
• Katz, M. D. (2001). ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults. American Journal of Health-system Pharmacy, 58(17).
• Katz, M. D. (2001). Obesity management and evidence-based pharmacy practice. American Journal of Health-System Pharmacy, 58(17), 1595-.
  More info

  PMID: 11556652;
• Katz, M. D. (2001). Obesity management and evidence-based pharmacy practice. American Journal of Health-System Pharmacy, 58(17), 1595-1595. doi:10.1093/ajhp/58.17.1595
• Katz, M. D. (2000). Use of alternative products: where's the beef?. Western Journal of Medicine, 172(2), 95-.
  More info

  PMID: 10693369;PMCID: PMC1070763;
• Katz, M. D., Scherger, J. E., Schellhaze, K., & Ellsworth, A. (1998). Levothyroxine bioequivalence. Journal of Family Practice, 46(2), 108-109.
  More info

  PMID: 9487307;
• Katz, M. D., Draugalis, J. R., & Lai, R. P. (1995). HIV infection and AIDS: Attitudes and knowledge of Arizona pharmacists. Annals of Pharmacotherapy, 29(12), 1218-1223.
  More info

  PMID: 8672824;Abstract: OBJECTIVE: To assess Arizona pharmacists' attitudes and knowledge regarding HIV infection and AIDS. METHODS: Mailing of a 7-page survey, which included demographic and attitudinal items, as well as preparedness, comfort, and knowledge scales. SETTING: Randomly selected pharmacists registered and residing in Arizona. PARTICIPANTS: Of the 479 pharmacists surveyed, 41 were removed from the sample because they had moved with no forwarding address, were retired or not practicing, or had died. The response rate was 46% for the remaining 438 pharmacists. A final sample size of 199 was obtained. RESULTS: The respondents had a high level of preparedness and comfort in addition to positive attitudes. Overall, their knowledge level was low. Inpatient pharmacists had a higher level of therapeutic knowledge (p < 0.001) and were more willing to work with a person infected with HIV than were outpatient pharmacists (p = 0.05). Pharmacists who had attended at least 1 HIV/AIDS-related continuing education (CE) program had higher levels of preparedness (p < 0.0001), comfort (p = 0.01), and knowledge (p < 0.0001) than those who had not. The majority of respondents believed that an HIV/AIDS CE program should be mandatory. CONCLUSIONS: Although Arizona pharmacists feel prepared, are comfortable, and have positive attitudes regarding patients with HIV/AIDS, their level of knowledge is low. The results of this study may be used by CE providers to design programs to meet the educational needs of pharmacists.
• Katz, M. D. (1993). Anticholinergics increase risk of adverse drug reactions in elderly.. Provider (Washington, D.C.), 19(4), 53-.
  More info

  PMID: 10125032;
• Katz, M. D. (1993). Are elderly patients intrinsically more sensitive to drugs?. Drug Therapy, 23(1), 57-.
• Katz, M. D., & Bressler, R. (1993). Drug therapy for geriatric depression.. Drugs & aging, 3(3), 195-219. doi:10.2165/00002512-199303030-00002
  More info

  Depression is a common problem in elderly patients. The identification and treatment of depression may be more complex in older than in younger patients because of co-existing illnesses and concurrent drug therapy. In addition, a variety of medical conditions and drugs can cause depression. The pharmacology and pharmacokinetics of the cyclic antidepressants have been extensively studied. These agents are hepatically metabolised, often to an active agent. The clearance of the parent compound and the active metabolite(s) may be reduced in elderly patients, causing drug accumulation and increased toxicity. The cyclic antidepressants interact with a variety of neurotransmitters and their receptors. While these effects explain many of the adverse effects of the cyclic antidepressants, it is not clear whether the noradrenergic and serotoninergic effects of such drugs explain their antidepressant effects. Cyclic antidepressant therapy is associated with a variety of adverse effects, including sedation, anticholinergic effects and effects caused by alpha-adrenergic blockade. The cyclic antidepressants differ in their relative ability to cause these adverse effects. The newer cyclic antidepressants such as the selective serotonin reuptake inhibitors are relatively free of sedative and anticholinergic effects, but cause insomnia, nausea and possibly cardiac arrhythmias. All cyclic antidepressants appear to be equally effective. Therefore, the choice of a cyclic antidepressant for a specific patient must be based on several factors, including the risk of adverse effects. In elderly patients, the initial dose of cyclic antidepressants should be lower than the usual dose recommended for younger adults, and titrated slowly. All antidepressants require at least 2 to 3 weeks for their antidepressant effects to be seen. Because depression is a relapsing disease, maintenance antidepressant therapy may be indicated to reduce the risk of recurrent depression. The monoamine oxidase (MAO) inhibitors are effective antidepressants, especially in atypical depression. However, the adverse effects and risk of potentially lethal drug interactions of the older agents preclude their routine use. However, the new reversible MAO inhibitors may prove to be a well tolerated alternative in older patients. Antidepressant therapy should not be avoided simply because of a patient's age. However, the clinician must be conservative in the use of cyclic antidepressants in elderly patients and monitor closely for adverse drug reactions.
• Schram, K. H., Petersen, E., Nakao, T., Nakano, K., Mcclure, T. D., Katz, M. D., & Hammargren, W. M. (1993). Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS.. Clinica chimica acta; international journal of clinical chemistry, 218(2), 169-83. doi:10.1016/0009-8981(93)90181-3
  More info

  Using boronate gel affinity chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), a method for the simultaneous determination of 12 urinary modified nucleosides has been developed. The RP-HPLC fractions were identified by gas chromatography/mass spectrometry analysis. The HPLC quantitation of urinary nucleoside levels before and after surgery of cancer patients suggested that urinary 5'-deoxy-5'-methylthioadenosine and N-[(9-beta-D-ribofuranosyl-9H-purine-6-yl) carbamoyl]-L-threonine (t6A) levels were helpful in monitoring therapeutic effects in cancer patients. From the fact that molar ratios of urinary N2,N2-dimethylguanosine (m2 2G)pseudouridine (psi) and t6A/psi in cancer patients were lower than those of normal or post-surgical cancer patients, the increase of rRNA content in cancer tissues growing rapidly was estimated using the stoichiometric relationship between the ratio of the number of residues of their modified nucleoside in RNAs and the proportion of rRNA to total RNAs in average tissues of whole body. Furthermore, from the estimation of RNA turnover using urinary nucleoside levels, it was found that the half-lives of rRNA rather than tRNA of patients with cancer and those of both RNAs in the case of acquired immunodeficiency syndrome (AIDS) were extremely short compared with those of the normal. Thus, we discovered that the selected urinary modified nucleosides were very useful as a biological marker of whole-body RNA turnover in patients with cancer and AIDS.
• Meeks, M. L., Mahaffey, K. W., & Katz, M. D. (1992). Danazol increases the anticoagulant effect of warfarin. Annals of Pharmacotherapy, 26(5), 641-642.
  More info

  PMID: 1591422;Abstract: OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English- language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction between danazol and warfarin, resulting in bleeding complications. There are at least two other reported cases of this interaction. This interaction may be attributable to several mechanisms. Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems. CONCLUSIONS: Based on this report and other published cases, clinicians must be aware that danazol may increase the anticoagulant effect of warfarin. Patients receiving warfarin who are prescribed danazol must be monitored closely to prevent excessive anticoagulation and subsequent bleeding. Studies are needed to determine the frequency of this interaction and its underlying mechanisms.
• Hammargren, W. M., Schram, K. H., Nakano, K., Yasaka, T., Katz, M., & Petersen, E. (1991). Analysis of urinary nucleosides from AIDS patients using GC/MS. Nucleosides and Nucleotides, 10(1-3), 659-661.
• Katz, M. D. (1990). Seeking a part-time faculty position with a college of pharmacy. American Journal of Hospital Pharmacy, 47(5), 1008-.
• Katz, M. D., & Erstad, B. L. (1989). Octreotide, a new somatostatin analogue.. Clinical pharmacy, 8(4), 255-73.
  More info

  The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects and drug interactions, dosage, availability and cost, and indications for use of octreotide, a new synthetic analogue of the peptide hormone somatostatin (SS), are reviewed. Like SS, octreotide suppresses secretion of pituitary growth hormone (GH) and thyrotropin and decreases release of a variety of pancreatic islet cell hormones including insulin, glucagon, and vasoactive intestinal peptide (VIP). Octreotide also reduces splanchnic blood flow, gastric acid secretion, GI motility, and pancreatic exocrine function and alters the absorption of water, electrolytes, and nutrients from the GI tract. The elimination half-life of i.v. octreotide is 72-98 minutes, compared with 2-3 minutes for i.v. SS. Usual administration of octreotide is by the i.v. or s.c. route. Octreotide has been studied in the treatment of hormone-secreting pituitary tumors and pancreatic islet cell tumors. Octreotide therapy lowers GH secretion and improves clinical symptoms in patients with acromegaly and may suppress clinical symptoms to a greater degree than bromocriptine. Patients with carcinoid syndrome and VIP-secreting tumors (vipomas) have had substantial improvement in clinical symptoms with administration of octreotide. This agent does not appear to be effective in the treatment of nonvariceal upper GI bleeding and acute pancreatitis; its relative usefulness in the treatment of variceal bleeding is not established. Adverse effects associated with octreotide therapy generally have been mild, including pain or burning at the injection site, abdominal pain, and diarrhea. Octreotide has been shown to interfere with absorption of oral cyclosporine. Standard initial therapy is octreotide acetate 50-100 micrograms s.c. every 8-12 hours, with titration based on clinical and biochemical effects. Up to 3000 micrograms/day of octreotide acetate has been administered to patients with acromegaly without serious adverse effect. Octreotide is marketed under the brand name Sandostatin and is available in 1-mL ampuls containing 50, 100, and 500 micrograms of octreotide acetate. Because the conditions for which octreotide appears to be most effective are uncommon, the drug should be considered for addition to the formulary in tertiary-care institutions only; addition of octreotide to the formulary of a community hospital is probably unnecessary. The synthetic analogue octreotide is longer acting and more specific in pharmacologic action than SS.(ABSTRACT TRUNCATED AT 400 WORDS)
• Matsunga, S. K., Plezia, P. M., Karol, M. D., Katz, M. D., Camilli, A. E., & Benowitz, N. L. (1989). Effects of passive smoking on theophylline clearance. Clinical Pharmacology and Therapeutics, 46(4), 399-407.
  More info

  PMID: 2791443;Abstract: Theophylline disposition was examined in seven passive smokers, defined as nonsmokers with long-term exposure to cigarette smoke, and seven age-matched nonsmokers with minimal smoke exposure. Subjects were given an intravenous infusion of aminophylline (6 mg/kg) and blood samples were drawn before and during the 48-hour postinfusion period. Clearance for passive smokers was 6.01 × 10-2 L/hr · kg and for nonsmokers, clearance was 4.09 × 10-2 L/hr · kg (p < 0.025). Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p < 0.05). The mean residence time for passive smokers was 9.89 hours. For nonsmokers, the mean residence time was 13.11 hours (p < 0.05). These measurements were statistically different, whereas there was no difference in volume of distribution between the groups, suggesting that passive smokers metabolize theophylline more rapidly than nonsmokers. Plasma and urine cotinine and nicotine concentrations were measured in all subjects. There was a significant difference between the subject groups in plasma (p < 0.004) and urine (p < 0.002) cotinine concentrations. Theophylline clearance correlated with both plasma (r = 0.73, p < 0.01) and urine (r = 0.79, p < 0.01) cotinine concentrations. Additional studies should be conducted to further define the pharmacokinetic characteristics of passive smokers and to assess the effects of passive smoking on drugs metabolized by the mixed function oxidase system. © 1989.
• Rose, C., Katz, M. D., & Erstad, B. L. (1988). Treatment of severe cryptosporidium-related diarrhea with octreotide in a patient with AIDS.. Drug intelligence & clinical pharmacy, 22(2), 134-6. doi:10.1177/106002808802200206
  More info

  Cryptosporidiosis commonly causes severe diarrhea in immunosuppressed patients. There currently are no antiparasitic drugs consistently effective for this infection. This case describes a 26-year-old hemophiliac patient with acquired immunodeficiency syndrome and cryptosporidiosis whose diarrhea improved with continuous intravenous administration of a long-acting somatostatin analog, octreotide. Somatostatin has a variety of inhibitory effects on gastrointestinal hormones as well as a possible nonspecific effect on gastrointestinal mucosal fluid and electrolyte secretion. The somatostatin analog should be considered for patients with secretory diarrhea refractory to other forms of therapy.
• Katz, M. D., & Lor, E. (1986). Acute interstitial nephritis associated with intermittent rifampin use. Drug Intelligence and Clinical Pharmacy, 20(10), 789-792.
  More info

  PMID: 3769771;
• Nugent, S., Katz, M. D., & Little, T. E. (1986). Baclofen overdose with cardiac conduction abnormalities: Case report and review of the literature. Journal of Toxicology - Clinical Toxicology, 24(4), 321-328.
  More info

  PMID: 3018274;Abstract: Cardiac conduction abnormalities and hypertension developed in a patient who ingested approximately 500 mg of baclofen (Lioresal®). The patient also exhibited the more common features of baclofen overdose including coma, respiratory depression, hypotonia, and hyporeflexia. A review of the literature and a discussion of the interesting manifestations and treatment of baclofen overdose are included.
• Katz, M. D., Fritz, W. L., & Lor, E. (1984). Heroin: Should it be legalized for the treatment of cancer pain?. Arizona Medicine, 41(9), 602-603.
  More info

  PMID: 6497687;

Presentations

• Katz, M. (2020, December). Creating residency programs to develop the internal medicine specialty workforce. Saudi Society for Clinical Pharmacy Internal Medicine PSN, national webinar. virtual: SSCP IM PSN.
• Katz, M. (2020, December). Latest trends that advance pharmacy practice and curriculum revision. Ubon Rathchathani University College of Pharmacy, Thailand. virtual: UBU.
• Katz, M. (2020, February). Critical responsibilities and roles for pharmacists in patient care. DUPHAT 2020. Dubai, UAE: DUPHAT.
• Katz, M. (2020, February). Latest trends that advance pharmacy practice. DUPHAT 2020. Dubai, UAE: DUPHAT.
• Katz, M. (2020, July). Pharmacy education and training in the US: Opportunities and challenges. Indian Association of Colleges of Pharmacy Annual Meeting. Virtual: IACP.
• Katz, M. (2020, March). ACPE International Certification. King Abdulaziz University. Jeddah, KSA: King Abdulaziz University.
• Katz, M. (2020, November). Pharmacy education and training in the US: Opportunities and challenges, keynote speaker. Virtual Conference on Confluence of Biomedical and Allied Sciences for Development of Pharmaceuticals, Shoolin University, Solin, India. virtual: Shoolin University.
• Katz, M. (2019, April). International Pharmacy Education and Training. university seminar. Tabuk, Saudi Arabia: University of Tabuk.
• Katz, M. (2019, August). Global training for the pharmacist of the future. Japan Society for Pharmaceutical Education Annual Meeting. Osaka, Japan: JSPE.
• Katz, M. (2019, March). Patient Assessment. DUPHAT 2019. Dubai, UAE: DUPHAT.
• Katz, M. (2019, March). Pharmacist Wellness. DUPHAT 2020. Dubai, UAE.
• Katz, M. (2019, March). Pharmacy Education and Professionalism. Pharmacy seminar. Shizuoka, Japan: University of Shizuoka.
• Katz, M. (2019, October). Developing International pharmacy student experiences. seminar. El Paso, TX: UTEP School of Pharmacy.
• Katz, M. (2019, October). Pharmacy Education. university seminar. Osaka, Japan: University of Osaka.
• Katz, M. (2017, April). Pharmacy training and education in the US. International Exposition and Conference on Higher Education. Riyadh, Saudi Arabia.
• Katz, M. (2017, April). Pharmacy training and education in the US. King Abdulaziz University Symposium. Jeddah, Saudi Arabia.
• Katz, M. (2017, April). Pharmacy training and education in the US. King Faisal University Symposium. Al Ahsa, Saudi Arabia.
• Katz, M. (2017, July). Becoming a more effective preceptor. Ahmad Dahlan University Symposium. Yogjakarta, Indonesia.
• Katz, M. (2017, July). Becoming a more effective preceptor. Asian Conference on Clinical Pharmacy. Yogjakarta, Indonesia.
• Katz, M. (2017, July). Becoming an effective preceptor. Airllanga University Symposium. Surabayya, Indonesia.
• Katz, M. (2017, July). Collaborative models for international cooperation: The US-Thai Pharmacy Consortium experience. Asian Conference on Clinical Pharmacy. Yogjakarta, Indonesia.
• Katz, M. (2017, July). Improving clinical pharmacy through collaboration. Asian Conference on Clinical Pharmacy. Yogjakarta, Indonesia.
• Katz, M. (2017, November). Pharmacy training and education in the US. UCIMED Symposium. San Jose, Costa Rica.
• Katz, M. (2016, July). International Programs for Student Pharmacists. Asian Conference on Clinical Pharmacy. Seoul, south Korea.
• Katz, M. (2016, July). Pharmacy Education in the US. Seoul National University pharmacy conference. Seoul, South Korea.
• Katz, M. (2016, June). Pharmacy Education and Training in the US. Chiang Mai University pharmacy conference. Chiang Mai, Thailand.
• Katz, M. (2016, June). Residency Assessment. US-Thai Pharmacy Consortium Conference. Khon Kaen, Thailand.
• Katz, M. (2016, March). Pharmacy Education in the US. invited presentation at Jordan University of Science and Technology. Irbid, Jordan.
• Katz, M. (2016, May). Collaborative models for International Cooperation. Association of Southeast Asian Nations pharmacy conference. Bangkok, Thailand.
• Katz, M. (2016, May). Transformative Education for Pharmacy Students. Thailand National Conference on Pharmacy Education.
• Katz, M. (2016, November). Applying Pharmacoeconomics to clinical decision-making. Osaka University pharmacy conference. Osaka, Japan.
• Katz, M. (2016, November). Pharmacy Education and Practice in the US. Tokushima University pharmacy conference. Tokushima, Japan.
• Katz, M. (2016, October). Pharmacy Education and Practice in the US. Meijo University pharmacy conference. Nagoya, Japan.
• Katz, M. (2016, October). Pharmacy Residency Training. Kobe City Hospital pharmacy conference. Kobe, Japan.
• Katz, M. (2015, April). Clinical Pharmacy Training in the US. King Saud University Medical City. Riyadh, Saudi Arabia: King Saud University Medical City.
• Katz, M. (2015, April). Clinical Pharmacy Training in the US. Sidra Medical and Research Center. Doha, Qatar: Sidra Medical and Research Center.
• Katz, M. (2015, August). Interprofessional Education. Chulalongkorn University. Bangkok, Thailand: Chulalongkorn University.
• Katz, M. (2015, August). Pharmacy Education and Residency Training: US and Thailand. Mahidol University. Bangkok, Thailand: Mahidol University.
• Katz, M. (2015, January). Pharmacy Education and Training. Chiang Mai University. Chiang Mai, Thailand: Chiang Mai University.
• Katz, M. (2015, January). Pharmacy Residency Training. Chiang Mai University. Chiang Mai, Thailand: Chiang Mai University.
• Katz, M. (2015, June). Pharmacy Education in the 21st Century. Mahasarakham University. Mahasarakham, Thailand: Mahasarakham University.
• Katz, M. (2015, June). Pharmacy Residency Training. Mahasarakham University. Mahasarakham, Thailand: Mahasarakham University.
• Katz, M. (2015, June). Preceptor Development. Mahasarakham University. Mahasarakham, Thailand: Mahasarakham University.
• Katz, M. (2015, June). US-Thai Pharmacy Consortium:A successful 20 Year Education and Training Partnership. Asian Conference on Clinical Pharmacy. Bangkok, Thailand: Asian Conference on Clinical Pharmacy.
• Katz, M. (2015, March). US Training of Clinical Pharmacy Faculty: Kingdom of Saudi Arabia Experience. 7th International Conference on Health Issues in Arab Communities. Muscat, Oman: Oman Ministry of Health.
• Katz, M. (2015, November). Clinical Pharmacy Education and Training at UACOP. Kobe Gakuin University. Kobe, Japan: Kobe Gakuin University.
• Katz, M. (2015, October). Applying Pharmacoeconomics to Clinical Decision-Making. Osaka University. Osaka, Japan: Osaka University.
• Katz, M. (2015, October). International Programs at UACOP. Osaka University. Osaka, Japan: Osaka University.
• Katz, M. (2015, October). Pharmacy Education and Training in the US. Osaka University. Osaka, Japan: Osaka University.
• Katz, M., & Nakagawa, S. (2015, June). International Programs for Student Pharmacists. Asian Conference on Clinical Pharmacy. Bangkok, Thailand: Asian Conference on Clinical Pharmacy.

Poster Presentations

• Katz, M., & Choi, B. (2017, September). Assessment of international learnnig experiences through the University of Arizona College of Pharmacy IPSF chapter. FIP World Congress. Seoul, South Korea.
• Katz, M., & Nakagawa, S. (2017, July). Assessment of Japan and American student study abroad experiences. Asian Conference on Clinical Pharmacy. Yogjakarta, Indonesia.
• Katz, M., & Nakagawa, S. (2016, July). International Programs for Student Pharmacists. Asian Conference on Clinical Pharmacy. Seoul, South Korea.
• Katz, M., & Henry, N. (2015, June). Approaches to Effective Management of Hepatitis C: A Global Epidemic. Asian Conference on Clinical Pharmacy. Bangkok, Thailand: Asian Conference on Clinical Pharmacy.
• Katz, M., & Henry, N. (2015, June). Quantifying and Preventing Fall Risk in Older Adults: A Multi-National Literature REview. Asian Conference on Clinical Pharmacy. Bangkok, Thailand: Asian Conference on Clinical Pharmacy.
• Katz, M., & Nakagawa, S. (2015, June). Japan Student Pharmacist Trip to Study American Pharmacy. Asian Conference on Clinical Pharmacy. Bangkok, Thailand: Asian Conference on Clinical Pharmacy.
• Ashy, N., Katz, M., Huckleberry, Y., & Honkonen, M. N. (2014, December). Evaluation of Hypoglycemia and Glycemic Control Following Transition from Intravenous Insulin Infusion to Subcutaneous Therapy. ASHP Midyear.